IRVINE, Calif., April 14, 2009 (GLOBE NEWSWIRE) -- SenoRx Inc. (Nasdaq:SENO) today announced the introduction of StarchMark, the company's newest addition to its line of biopsy site markers. SenoRx is a market leader in breast biopsy markers, with the widest array of advanced markers offering enhanced visualization in all three imaging modalities -- stereotactic, ultrasound and MRI. StarchMark is the first and only breast biopsy marker that uses polysaccharide (starch) pellets to help manage and control bleeding. StarchMark received 510(k) clearance in August 2008.
